NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
To determine the safety and tolerability of adding durvalumab to mFOLFIRINOX prior to surgery
in patients with resectable or borderline resectable pancreatic adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Australasian Gastro-Intestinal Trials Group
Collaborators:
The University of New South Wales Walter and Eliza Hall Institute of Medical Research